omniture
logo
Search
齐鲁制药上海临床研究中心
Media Room

Photo News

rss
Qilu Pharmaceutical's Three Clinical Studies on Cancer Immunotherapy Presented at ASCO 2024

Qilu Pharmaceutical's Three Clinical Studies on Cancer Immunotherapy Presented at ASCO 2024

2024-06-07 14:51 1610
Results from the Clinical Trial of Qilu Pharmaceutical's Novel Anticancer Agent Iparomlimab and Tuvonralimab (QL1706) Featured in Oral Presentation at the ESGO Annual Meeting

Results from the Clinical Trial of Qilu Pharmaceutical's Novel Anticancer Agent Iparomlimab and Tuvonralimab (QL1706) Featured in Oral Presentation at the ESGO Annual Meeting

2024-03-04 16:53 1833
Qilu Pharmaceutical announces the latest results from its clinical study on QL1706, in combination with chemotherapy, as a first-line treatment for recurrent or metastatic cervical cancer

Qilu Pharmaceutical announces the latest results from its clinical study on QL1706, in combination with chemotherapy, as a first-line treatment for recurrent or metastatic cervical cancer

2023-10-25 22:33 2096
Qilu Pharmaceutical announces the latest results from its clinical study on QL1706, in combination with chemotherapy, as a first-line treatment for recurrent or metastatic cervical cancer

Qilu Pharmaceutical announces the latest results from its clinical study on QL1706, in combination with chemotherapy, as a first-line treatment for recurrent or metastatic cervical cancer

2023-10-25 22:15 1971
Qilu Pharmaceutical Releases Latest Results of QL1706 plus Chemotherapy +/- Bevacizumab for the Treatment of Non-Small Cell Lung Cancer in the Phase II Study at ESMO Asia Congress 2022

Qilu Pharmaceutical Releases Latest Results of QL1706 plus Chemotherapy +/- Bevacizumab for the Treatment of Non-Small Cell Lung Cancer in the Phase II Study at ESMO Asia Congress 2022

2022-12-02 16:20 1498